Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda
Full Article
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
FT.com
0 shares
1 views